Effect of resveratrol combined on Exercise program on health-related outcomes of breast cancer survivors: randomized, double-blind clinical trial

INTERVENTION: G11.427.410.698.277 Home‐based exercise group with Resveratrol: The 20 participants in this group will do 12 weeks of aerobic exercise associated with strength exercise with their own body weight and flexibility of moderate intensity and duration of 45 minutes per session, performed three times a week . In addition, participants will take a daily supplementation, orally, of one capsule containing 500 mg Resveratrol during the twelve weeks of intervention. Home‐based physical exercise group with Placebo: The 20 participants in this group will do 12 weeks of aerobic exercise associated with strength exercise with their own body weight and flexibility of moderate intensity and duration of 45 minutes per session, performed three times a week . In addition, participants will take a daily oral supplementation of one capsule containing 500 mg of placebo during the twelve weeks of intervention. Resveratrol Group: The 20 participants in this group will take a daily supplementation, orally, of one capsule containing 500 mg Resveratrol during the twelve weeks of intervention. Capsules containing Resveratrol were obtained from the company Miligrama (composed of 99% of Trans‐Resveratrol). Control group: The 20 participants in this group will take a daily supplementation, orally, of one capsule containing 500 mg of placebo during the twelve weeks of intervention. SP6.051.227 CONDITION: Breast cancer; Breast Neoplasms; Personal history of malignant breast cancer; Family history of breast cancer C00‐D48 PRIMARY OUTCOME: Improvement of body composition, decrease in BMI and fat percentage, and maintenance of bone density, evaluated by a scale and a stadiometer, Filizola, São Paulo, Brazil, with an accuracy of 0.1 kg and 0.5 cm, respectively. As well as the percentage of fat and bone density, assessed by the x‐ray double‐beam absorptiometry method, with model equipment, Lunar Prodigy Primo, GE Healthcare. Data collected 1 week before the intervention and one week after the intervention ended. Improvement of cardiorespiratory capacity, assessed by submaximal aerobic test by Swain et al. SUPRA ATL treadmill, IMBRAMED, Brazil) and using the RS800CX, Polar Electro Oy Finland, frequency meter. The maximum VO2 will be estimated by the reserve HR and VO2 equations, the protocol of the American College of Sports Medicine. Data collected 1 week before the intervention and one week after the intervention ended. Inflammatory profile modulation, assessed by a blood collection of 4 ml of blood per tube to obtain plasma for cytokine analysis: IL‐6, IL‐1, IL‐4, IL‐10, TNF, and IFN. The samples will be analyzed by flow cytometry, Accuri C6 CSampler, BD Biosciences, and the data obtained were analyzed with FCAParray software, BD Biosciences. Blood tests collected 1 week before the intervention and one week after the intervention ended. SECONDARY OUTCOME: No Secondary Outcomes Expected INCLUSION CRITERIA: Postmenopause; high BMI; sedentary lifestyle (mild physical activity, less than 150 minutes per week, American College of Sports Medicine 2014)